Skip to main content
NIKA
OTC Life Sciences

Nika Q3: $352 Cash Left, Going Concern Doubt Reaffirmed, Controls Not Effective

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.35
Mkt Cap
$368.091M
52W Low
--
52W High
--
52W Position
Off High
Rel. Volume
Market data snapshot near publication time

Summary

Nika's Q3 2026 10-Q shows $352 of cash, a $9.05 million accumulated deficit and a reaffirmed going concern warning, with operations kept alive by $30,390 of related-party loans. Controls were again deemed ineffective, and roughly 197 million merger shares remain unissued.


Key Events · Earnings and Guidance · NIKA

  • Cash Nearly Exhausted at Quarter End

    Cash stood at $352 at September 30, 2026, down from $1,889 at December 31, 2025, against total liabilities of $349,014 owed to related parties.

  • Going Concern Doubt Reaffirmed

    The accumulated deficit reached $9,050,086 with no revenue generated to date, and management states substantial doubt about the ability to continue as a going concern.

  • Insider Loans Fund Operations

    Non-interest-bearing related-party advances of $30,390 received during the nine months covered a $31,927 operating cash burn; total due to related parties was $349,014.

  • Material Weaknesses Persist

    Management concluded disclosure controls and procedures were not effective, citing the lack of an audit committee and lack of separation of duties.


Analysis · NIKA · Life Sciences

With $352 of cash at September 30, 2026 against $349,014 owed to related parties, management has again flagged substantial doubt about the company's ability to continue as a going concern. No revenue was generated, and the nine-month operating shortfall of $31,927 was funded almost entirely by $30,390 of non-interest-bearing insider advances. Disclosure controls and procedures were also deemed not effective, with the lack of an audit committee and lack of separation of duties cited as the reasons. The only equity lever visible is the merger commitment: 7,140,000 of 204,205,027 promised shares have been issued, leaving roughly 197 million shares still to come—future dilution rather than cash. With essentially no liquidity, the next capital raise is the event that determines whether operations continue.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NIKA was trading at $0.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $368.1M. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NIKA - Latest Insights

NIKA
Aug 10, 2026, 1:39 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.510
Real-time Price: $0.350 info
Change: -$0.160 (-31%) info
Market Cap: $368.091M info
NIKA
May 12, 2026, 3:19 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.510
Real-time Price: $0.350 info
Change: -$0.160 (-31%) info
Market Cap: $368.091M info
NIKA
Mar 25, 2026, 3:47 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.7555
Real-time Price: $0.350 info
Change: -$0.4055 (-54%) info
Market Cap: $368.091M info
NIKA
Mar 06, 2026, 11:58 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7555
Real-time Price: $0.350 info
Change: -$0.4055 (-54%) info
Market Cap: $368.091M info